853 related articles for article (PubMed ID: 29254929)
1. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
2. MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis.
Watanabe R; Maeda T; Zhang H; Berry GJ; Zeisbrich M; Brockett R; Greenstein AE; Tian L; Goronzy JJ; Weyand CM
Circ Res; 2018 Aug; 123(6):700-715. PubMed ID: 29970365
[TBL] [Abstract][Full Text] [Related]
3. CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Nadler SG; Goronzy JJ; Weyand CM
J Am Coll Cardiol; 2019 Apr; 73(14):1811-1823. PubMed ID: 30975299
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
Southworth T; Plumb J; Gupta V; Pearson J; Ramis I; Lehner MD; Miralpeix M; Singh D
Respir Res; 2016 Oct; 17(1):124. PubMed ID: 27716212
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
6. Giant cell vasculitis is a T cell-dependent disease.
Brack A; Geisler A; Martinez-Taboada VM; Younge BR; Goronzy JJ; Weyand CM
Mol Med; 1997 Aug; 3(8):530-43. PubMed ID: 9307981
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
9. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptors 4 and 5 induce distinct types of vasculitis.
Deng J; Ma-Krupa W; Gewirtz AT; Younge BR; Goronzy JJ; Weyand CM
Circ Res; 2009 Feb; 104(4):488-95. PubMed ID: 19150884
[TBL] [Abstract][Full Text] [Related]
11. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.
De Vries LCS; Duarte JM; De Krijger M; Welting O; Van Hamersveld PHP; Van Leeuwen-Hilbers FWM; Moerland PD; Jongejan A; D'Haens GR; De Jonge WJ; Wildenberg ME
Inflamm Bowel Dis; 2019 Mar; 25(4):647-660. PubMed ID: 30668755
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint dysfunction in large and medium vessel vasculitis.
Watanabe R; Zhang H; Berry G; Goronzy JJ; Weyand CM
Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H1052-H1059. PubMed ID: 28314758
[TBL] [Abstract][Full Text] [Related]
13. Innate and Adaptive Immunity in Giant Cell Arteritis.
Akiyama M; Ohtsuki S; Berry GJ; Liang DH; Goronzy JJ; Weyand CM
Front Immunol; 2020; 11():621098. PubMed ID: 33717054
[TBL] [Abstract][Full Text] [Related]
14. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.
Zhang H; Watanabe R; Berry GJ; Vaglio A; Liao YJ; Warrington KJ; Goronzy JJ; Weyand CM
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):E970-E979. PubMed ID: 28115719
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
17. Targeting JAK/STAT pathway in Takayasu's arteritis.
Régnier P; Le Joncour A; Maciejewski-Duval A; Desbois AC; Comarmond C; Rosenzwajg M; Klatzmann D; Cacoub P; Saadoun D
Ann Rheum Dis; 2020 Jul; 79(7):951-959. PubMed ID: 32213496
[TBL] [Abstract][Full Text] [Related]
18. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
19. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
